CN106573011A - 取代的核苷、核苷酸和其类似物 - Google Patents

取代的核苷、核苷酸和其类似物 Download PDF

Info

Publication number
CN106573011A
CN106573011A CN201580045439.9A CN201580045439A CN106573011A CN 106573011 A CN106573011 A CN 106573011A CN 201580045439 A CN201580045439 A CN 201580045439A CN 106573011 A CN106573011 A CN 106573011A
Authority
CN
China
Prior art keywords
optionally substituted
alkyl
hydrogen
virus
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580045439.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN106573011A8 (zh
Inventor
L.M.布拉特
L.贝格尔曼
J.A.西蒙斯
D.B.史密斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biopharma Inc
Original Assignee
Alios Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alios Biopharma Inc filed Critical Alios Biopharma Inc
Priority to CN202310927143.6A priority Critical patent/CN117379452A/zh
Publication of CN106573011A publication Critical patent/CN106573011A/zh
Publication of CN106573011A8 publication Critical patent/CN106573011A8/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580045439.9A 2014-06-24 2015-06-22 取代的核苷、核苷酸和其类似物 Pending CN106573011A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310927143.6A CN117379452A (zh) 2014-06-24 2015-06-22 取代的核苷、核苷酸和其类似物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462016232P 2014-06-24 2014-06-24
US62/016,232 2014-06-24
US201462061770P 2014-10-09 2014-10-09
US62/061,770 2014-10-09
PCT/US2015/037001 WO2015200219A1 (en) 2014-06-24 2015-06-22 Substituted nucleosides, nucleotides and analogs thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310927143.6A Division CN117379452A (zh) 2014-06-24 2015-06-22 取代的核苷、核苷酸和其类似物

Publications (2)

Publication Number Publication Date
CN106573011A true CN106573011A (zh) 2017-04-19
CN106573011A8 CN106573011A8 (zh) 2017-07-11

Family

ID=54868668

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580045439.9A Pending CN106573011A (zh) 2014-06-24 2015-06-22 取代的核苷、核苷酸和其类似物
CN202310927143.6A Pending CN117379452A (zh) 2014-06-24 2015-06-22 取代的核苷、核苷酸和其类似物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310927143.6A Pending CN117379452A (zh) 2014-06-24 2015-06-22 取代的核苷、核苷酸和其类似物

Country Status (20)

Country Link
US (2) US9603864B2 (https=)
EP (2) EP3797782A1 (https=)
JP (3) JP6728075B2 (https=)
CN (2) CN106573011A (https=)
AU (2) AU2015280248B2 (https=)
CA (2) CA3207106A1 (https=)
DK (1) DK3160476T3 (https=)
EA (1) EA201692535A1 (https=)
ES (1) ES2841310T3 (https=)
HR (1) HRP20202014T1 (https=)
HU (1) HUE051986T2 (https=)
IL (1) IL249628A0 (https=)
LT (1) LT3160476T (https=)
MX (1) MX2016017383A (https=)
PH (1) PH12016502564A1 (https=)
SG (1) SG11201610599TA (https=)
SI (1) SI3160476T1 (https=)
SM (1) SMT202000716T1 (https=)
TW (1) TW201613612A (https=)
WO (1) WO2015200219A1 (https=)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107073002A (zh) * 2014-09-26 2017-08-18 里博科学有限责任公司 作为呼吸道合胞体病毒rna复制抑制剂的4’‑乙烯基取代的核苷衍生物
CN111542531A (zh) * 2017-09-18 2020-08-14 詹森生物制药有限公司 取代的核苷、核苷酸以及它们的类似物
CN112074506A (zh) * 2018-03-07 2020-12-11 埃默里大学 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途
CN112218533A (zh) * 2018-03-02 2021-01-12 詹纽瑞治疗公司 纳米颗粒组合物
CN112279877A (zh) * 2020-12-15 2021-01-29 南京颐媛生物医学研究院有限公司 一种核苷磷酸酯及其合成方法
CN113214320A (zh) * 2021-01-23 2021-08-06 河南泰丰生物科技有限公司 一种瑞德西韦化合物的制备方法
CN113461760A (zh) * 2021-09-06 2021-10-01 南京颐媛生物医学研究院有限公司 4-硫代脱氧胸苷衍生物及其抗乙肝病毒制药应用
CN113735929A (zh) * 2021-07-21 2021-12-03 海化生命(厦门)科技有限公司 一种抗冠状病毒的化合物及其制备方法与应用
US11306111B2 (en) 2017-07-31 2022-04-19 January Therapeutics, Inc. Organophosphate derivatives
CN114867351A (zh) * 2019-10-08 2022-08-05 埃默里大学 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途
CN115335387A (zh) * 2020-03-27 2022-11-11 住友化学株式会社 核酸寡聚物的制造方法
CN115515603A (zh) * 2020-04-14 2022-12-23 杨森制药公司 用于治疗戊型肝炎的双环和单环核苷类似物
WO2023030347A1 (zh) * 2021-09-01 2023-03-09 常晓宇 嘌呤核苷类药物预防或治疗冠状病毒感染性疾病的用途
WO2023142803A1 (zh) * 2022-01-28 2023-08-03 北京恩泰伟医药科技有限公司 抗病毒化合物及其用途
CN116589510A (zh) * 2023-04-20 2023-08-15 安徽大学 一种氟代苄基核糖中间体的制备方法与应用

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
SG10201913554YA (en) 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
US9598457B2 (en) 2012-12-21 2017-03-21 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
BR112015014457A2 (pt) * 2012-12-21 2017-11-21 Alios Biopharma Inc composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
CA2908313A1 (en) 2013-04-05 2014-10-09 Alios Biopharma, Inc. Hepatitis c viral infection treatment using a combination of compounds
AU2014302711A1 (en) 2013-06-26 2015-12-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
MX2015017556A (es) 2013-06-26 2016-05-09 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos.
WO2015054465A1 (en) * 2013-10-11 2015-04-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
HUE051986T2 (hu) 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
MA40031A (fr) 2014-06-24 2015-12-30 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
WO2016069489A1 (en) 2014-10-28 2016-05-06 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41213A (fr) * 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
US10208045B2 (en) 2015-03-11 2019-02-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
CN105503787A (zh) * 2015-12-31 2016-04-20 阜阳欣奕华材料科技有限公司 一种索非布韦中间体的纯化方法
US9988416B2 (en) * 2016-03-24 2018-06-05 Novartis Ag Alkynyl nucleoside analogs as inhibitors of human rhinovirus
EA201892448A1 (ru) * 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
EP3510040A4 (en) 2016-09-09 2020-06-03 Calithera Biosciences, Inc. EKTONUCLEOTIDASE INHIBITORS AND METHOD FOR USE THEREOF
EP3556764A4 (en) 2016-12-16 2021-01-06 Gifu University NUCLEOSIDE DERIVATIVE AND USE FOR IT
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
CA3059777C (en) 2017-05-01 2023-02-21 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
JP7173467B2 (ja) 2017-10-31 2022-11-16 ヤマサ醤油株式会社 ヌクレオシド誘導体及びその利用
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
CN113811360A (zh) 2019-03-06 2021-12-17 葛兰素史密斯克莱知识产权（第2 号）有限公司 用于hiv治疗的化合物
KR20240113860A (ko) * 2019-04-05 2024-07-23 가부시기가이샤 닛뽕쇼꾸바이 가교형 인공 뉴클레오시드의 제조
JP2023512656A (ja) 2020-01-27 2023-03-28 ギリアード サイエンシーズ， インコーポレイテッド ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN113387954B (zh) * 2020-03-11 2024-03-19 上海特化医药科技有限公司 一种瑞德西韦中间体的制备方法
KR20220153619A (ko) 2020-03-12 2022-11-18 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오사이드의 제조 방법
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CA3167268A1 (en) * 2020-03-27 2021-09-30 Ioannis PAPASOTIRIOU Nucleotide analogues for the treatment of coronaviruses
CA3172483A1 (en) 2020-04-06 2021-10-14 Scott Ellis Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
PE20230618A1 (es) 2020-06-24 2023-04-14 Gilead Sciences Inc Analogos de nucleosido de 1'-ciano y usos de los mismos
IL300412A (en) 2020-08-24 2023-04-01 Gilead Sciences Inc Phospholipid compounds and their uses
IL300453A (en) 2020-08-27 2023-04-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
WO2022174194A1 (en) * 2021-02-15 2022-08-18 Emory University 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
MX2023011870A (es) * 2021-04-09 2023-12-07 Univ Emory Análogos de nucleósidos y de nucleótidos como agentes antivirales para coronavirus y otros virus.
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial
AU2022306289A1 (en) 2021-07-09 2024-01-18 Aligos Therapeutics, Inc. Anti-viral compounds
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
WO2023069495A1 (en) * 2021-10-19 2023-04-27 Alnylam Pharmaceuticals, Inc. Oligonucleotides with 2'-deoxy-2'-f-2'-c-methyl nucleotides
US11541071B1 (en) 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
IL315480A (en) 2022-03-15 2024-11-01 Rome Therapeutics Inc Compounds and methods for treating disease
US20250282812A1 (en) * 2022-04-20 2025-09-11 Shanghai Institute Of Materia Medica , Chinese Academy Of Sciences Antiviral nucleoside analogue, and pharmaceutical composition and use thereof
US20260115216A1 (en) * 2022-08-10 2026-04-30 Kyushu University, National University Corporation Nucleic acid precursor
WO2024086592A2 (en) * 2022-10-17 2024-04-25 Emory Unversity 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040259934A1 (en) * 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
CN1646141A (zh) * 2000-10-18 2005-07-27 法玛塞特有限公司 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
WO2005020884A3 (en) * 2003-05-14 2006-06-22 Idenix Cayman Ltd Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
CN102421293A (zh) * 2009-03-20 2012-04-18 艾丽奥斯生物制药有限公司 取代的核苷和核苷酸类似物
CN102558261A (zh) * 2010-12-17 2012-07-11 中国科学院大连化学物理研究所 一种核苷酸类似物及其合成和应用
CN103209987A (zh) * 2010-09-22 2013-07-17 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
CN103687866A (zh) * 2011-05-19 2014-03-26 Rfs制药公司 用于治疗病毒性感染的嘌呤单磷酸酯前药
CN105377868A (zh) * 2013-04-12 2016-03-02 艾其林医药公司 用于治疗hcv的高活性核苷衍生物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
SK286630B6 (sk) 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
TW200500375A (en) * 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
WO2005020885A2 (en) * 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2006033709A2 (en) 2004-07-29 2006-03-30 Metabasis Therapeutics, Inc. Novel nucleoside derivatives
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
WO2008104893A2 (en) * 2007-02-28 2008-09-04 The Governors Of The University Of Alberta Compounds for preventing or treating viral infections and methods of use thereof
AR072906A1 (es) 2008-08-06 2010-09-29 Novartis Ag Nucleosidos modificados utiles como antivirales
WO2010108135A1 (en) * 2009-03-20 2010-09-23 Alios Biopharma, Inc. Protected nucleotide analogs
EP2619215B1 (en) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
WO2012040126A1 (en) * 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
CA2819041A1 (en) 2010-12-22 2012-06-28 Alios Biopharma, Inc. Cyclic nucleotide analogs
AU2012357940B2 (en) 2011-12-20 2017-02-16 Riboscience Llc 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
SG10201913554YA (en) 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
CA2860234A1 (en) * 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
WO2013142159A1 (en) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US8846896B2 (en) 2012-03-21 2014-09-30 Alios Biopharma, Inc. Methods of preparing substituted nucleotide analogs
GEP201706721B (en) 2012-03-21 2017-08-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
FR3000193B1 (fr) 2012-12-20 2015-01-16 Msc & Sgcc Procede et dispositif de mesure de la verticalite sur un recipient
US9598457B2 (en) 2012-12-21 2017-03-21 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
BR112015014457A2 (pt) 2012-12-21 2017-11-21 Alios Biopharma Inc composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
WO2014164533A1 (en) 2013-03-11 2014-10-09 Vertex Pharmaceuticals Incorporated Methods of stereoselective synthesis of substituted nucleoside analogs
CA2908313A1 (en) 2013-04-05 2014-10-09 Alios Biopharma, Inc. Hepatitis c viral infection treatment using a combination of compounds
AU2014302711A1 (en) 2013-06-26 2015-12-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
MX2015017556A (es) 2013-06-26 2016-05-09 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos.
LT3043803T (lt) 2013-09-11 2022-08-10 Emory University Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimas
WO2015054465A1 (en) 2013-10-11 2015-04-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
MA40031A (fr) 2014-06-24 2015-12-30 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
AU2015280245A1 (en) 2014-06-24 2017-01-05 Alios Biopharma, Inc. Methods of preparing substituted nucleotide analogs
HUE051986T2 (hu) 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
CA2955604A1 (en) 2014-07-22 2016-01-28 Alios Biopharma, Inc. Methods for treating paramyxoviruses
PE20170673A1 (es) 2014-08-05 2017-05-22 Alios Biopharma Inc Terapia de combinacion para tratar una paramixovirus
WO2016069489A1 (en) 2014-10-28 2016-05-06 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
TW201811339A (zh) 2016-08-12 2018-04-01 美商艾洛斯生物製藥公司 經取代之核苷、核苷酸及其類似物
US20180117042A1 (en) 2016-10-27 2018-05-03 Alios Biopharma, Inc. Methods for treating respiratory syncytial virus infection

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646141A (zh) * 2000-10-18 2005-07-27 法玛塞特有限公司 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
US20040259934A1 (en) * 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
WO2005020884A3 (en) * 2003-05-14 2006-06-22 Idenix Cayman Ltd Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
CN102421293A (zh) * 2009-03-20 2012-04-18 艾丽奥斯生物制药有限公司 取代的核苷和核苷酸类似物
CN103209987A (zh) * 2010-09-22 2013-07-17 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
CN102558261A (zh) * 2010-12-17 2012-07-11 中国科学院大连化学物理研究所 一种核苷酸类似物及其合成和应用
CN103687866A (zh) * 2011-05-19 2014-03-26 Rfs制药公司 用于治疗病毒性感染的嘌呤单磷酸酯前药
CN105377868A (zh) * 2013-04-12 2016-03-02 艾其林医药公司 用于治疗hcv的高活性核苷衍生物

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107073002B (zh) * 2014-09-26 2019-10-15 里博科学有限责任公司 作为呼吸道合胞体病毒rna复制抑制剂的4’-乙烯基取代的核苷衍生物
CN107073002A (zh) * 2014-09-26 2017-08-18 里博科学有限责任公司 作为呼吸道合胞体病毒rna复制抑制剂的4’‑乙烯基取代的核苷衍生物
US11306111B2 (en) 2017-07-31 2022-04-19 January Therapeutics, Inc. Organophosphate derivatives
CN111542531B (zh) * 2017-09-18 2024-07-19 詹森生物制药有限公司 取代的核苷、核苷酸以及它们的类似物
CN111542531A (zh) * 2017-09-18 2020-08-14 詹森生物制药有限公司 取代的核苷、核苷酸以及它们的类似物
US11773126B2 (en) 2017-09-18 2023-10-03 Janssen Pharmaceuticals, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN112218533A (zh) * 2018-03-02 2021-01-12 詹纽瑞治疗公司 纳米颗粒组合物
CN112074506A (zh) * 2018-03-07 2020-12-11 埃默里大学 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途
CN112074506B (zh) * 2018-03-07 2024-10-11 埃默里大学 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途
CN114867351B (zh) * 2019-10-08 2024-04-23 埃默里大学 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途
CN114867351A (zh) * 2019-10-08 2022-08-05 埃默里大学 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途
US12522629B2 (en) 2020-03-27 2026-01-13 Sumitomo Chemical Company, Limited Method for producing nucleic acid oligomer
CN115335387A (zh) * 2020-03-27 2022-11-11 住友化学株式会社 核酸寡聚物的制造方法
CN115515603A (zh) * 2020-04-14 2022-12-23 杨森制药公司 用于治疗戊型肝炎的双环和单环核苷类似物
CN112279877B (zh) * 2020-12-15 2021-08-06 南京颐媛生物医学研究院有限公司 一种核苷磷酸酯及其合成方法
CN112279877A (zh) * 2020-12-15 2021-01-29 南京颐媛生物医学研究院有限公司 一种核苷磷酸酯及其合成方法
CN113214320A (zh) * 2021-01-23 2021-08-06 河南泰丰生物科技有限公司 一种瑞德西韦化合物的制备方法
CN113735929A (zh) * 2021-07-21 2021-12-03 海化生命(厦门)科技有限公司 一种抗冠状病毒的化合物及其制备方法与应用
WO2023030347A1 (zh) * 2021-09-01 2023-03-09 常晓宇 嘌呤核苷类药物预防或治疗冠状病毒感染性疾病的用途
CN113461760B (zh) * 2021-09-06 2021-12-10 南京颐媛生物医学研究院有限公司 4-硫代脱氧胸苷衍生物及其抗乙肝病毒制药应用
CN113461760A (zh) * 2021-09-06 2021-10-01 南京颐媛生物医学研究院有限公司 4-硫代脱氧胸苷衍生物及其抗乙肝病毒制药应用
WO2023142803A1 (zh) * 2022-01-28 2023-08-03 北京恩泰伟医药科技有限公司 抗病毒化合物及其用途
CN116554249A (zh) * 2022-01-28 2023-08-08 北京恩泰伟医药科技有限公司 抗病毒化合物及其用途
CN116589510A (zh) * 2023-04-20 2023-08-15 安徽大学 一种氟代苄基核糖中间体的制备方法与应用
CN116589510B (zh) * 2023-04-20 2025-08-26 安徽大学 一种氟代苄基核糖中间体的制备方法与应用

Also Published As

Publication number Publication date
PH12016502564A1 (en) 2017-04-17
CA2952966C (en) 2024-10-29
ES2841310T3 (es) 2021-07-08
JP7449978B2 (ja) 2024-03-14
SMT202000716T1 (it) 2021-01-05
US20170143749A1 (en) 2017-05-25
AU2015280248B2 (en) 2021-04-08
EP3160476A4 (en) 2018-01-10
SI3160476T1 (sl) 2021-05-31
HUE051986T2 (hu) 2021-04-28
EP3797782A1 (en) 2021-03-31
CA3207106A1 (en) 2015-12-30
EP3160476B1 (en) 2020-09-30
AU2015280248A1 (en) 2017-01-12
DK3160476T3 (da) 2020-12-21
IL249628A0 (en) 2017-02-28
SG11201610599TA (en) 2017-01-27
JP2017519784A (ja) 2017-07-20
WO2015200219A1 (en) 2015-12-30
CA2952966A1 (en) 2015-12-30
US10307439B2 (en) 2019-06-04
CN106573011A8 (zh) 2017-07-11
US20150366888A1 (en) 2015-12-24
EP3160476A1 (en) 2017-05-03
AU2021204791B2 (en) 2023-12-07
US9603864B2 (en) 2017-03-28
AU2021204791A1 (en) 2021-08-05
JP2022116170A (ja) 2022-08-09
EA201692535A1 (ru) 2017-05-31
MX2016017383A (es) 2017-08-02
HRP20202014T1 (hr) 2021-04-02
TW201613612A (en) 2016-04-16
JP2020172511A (ja) 2020-10-22
CN117379452A (zh) 2024-01-12
LT3160476T (lt) 2021-04-12
JP6728075B2 (ja) 2020-07-22
JP7080928B2 (ja) 2022-06-06

Similar Documents

Publication Publication Date Title
JP7449978B2 (ja) 置換ヌクレオシド、ヌクレオチドおよびその類似体
CN106604734B (zh) 取代的核苷、核苷酸和其类似物
CN105829333A (zh) 取代的核苷、核苷酸及其类似物
CN105073766A (zh) 取代的核苷、核苷酸及其类似物
HK1236435A1 (en) Substituted nucleosides, nucleotides and analogs thereof
HK40049933A (en) Substituted nucleosides, nucleotides and analogs thereof for use in the treatment of viral infections
HK1236843B (en) Substituted nucleosides, nucleotides and analogs thereof for use in the treatment of viral infection
HK1236843A1 (en) Substituted nucleosides, nucleotides and analogs thereof for use in the treatment of viral infection
HK1236819A1 (en) Substituted nucleosides, nucleotides and analogs thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CI01 Publication of corrected invention patent application

Correction item: Priority

Correct: 62/016,232 2014.06.24 US|62/061,770 2014.10.09 US

Number: 16

Volume: 33

CI01 Publication of corrected invention patent application
CI02 Correction of invention patent application

Correction item: Priority

Correct: 62/016,232 2014.06.24 US|62/061,770 2014.10.09 US

Number: 16

Page: The title page

Volume: 33

CI02 Correction of invention patent application
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1236435

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20170419

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1236435

Country of ref document: HK